The Impact of Extent of Liver Resection Among Patients with Neuroendocrine Liver Metastasis: an International Multi-institutional Study
- PMID: 29980977
- DOI: 10.1007/s11605-018-3862-2
The Impact of Extent of Liver Resection Among Patients with Neuroendocrine Liver Metastasis: an International Multi-institutional Study
Abstract
Background: Liver resection in patients with neuroendocrine liver metastasis (NELM) provides a survival benefit, yet the optimal extent of resection remains unknown. We sought to examine outcomes of patients undergoing non-anatomic (NAR) versus anatomic liver resection (AR) for NELM using a large international cohort of patients.
Methods: Two hundred and fifty-eight patients who underwent curative intent liver resection from January 1990 to December 2016 were identified from eight institutions. Patients were excluded if they underwent concurrent ablation, had extrahepatic disease, underwent a debulking operation, or had mixed anatomic and non-anatomic resections. Overall (OS) and recurrence-free (RFS) survival were compared among patients based on the extent of liver resection (AR vs. NAR).
Results: Most primary tumors were located in the pancreas (n = 117, 45.4%) or the small intestine (n = 65, 25.2%). Liver resection consisted of NAR (n = 126, 48.8%) or AR (n = 132, 51.2%) resection. The overwhelming majority of patients who underwent NAR had an estimated liver involvement of < 50% (NAR 109, 97.3% vs. AR n = 82, 65.6%; P < 0.001). Patients who underwent NAR also had higher rates of primary tumor lymph node metastasis (NAR n = 79, 71.2% vs. AR n = 37, 33.6%; P < 0.001) and microscopically positive margins (R1) (NAR n = 29, 25.7% vs. AR n = 16, 12.5%; P = 0.009). After a median follow-up of 47.7 months, 48 (18.6%) patients died and 37.0% (n = 95) had evidence of disease recurrence. Patients who underwent AR had both longer median OS (not reached) and RFS (not reached) versus patients who underwent NAR (median OS 138.3 months; median RFS 31.3 months) (both P < 0.01). After controlling for patient and disease-related factors, extent of liver resection was independently associated with an increased risk of recurrence (HR 2.39, 95% CI 1.04-5.48; P = 0.04) but not death (HR 1.92, 95% CI 0.40-9.28; P = 0.42).
Conclusion: NAR was independently associated with a higher incidence of recurrence versus patients who undergo a formal anatomic hepatectomy among patients with NELM.
Keywords: Anatomic resection; Hepatectomy; Neuroendocrine tumors.
Similar articles
-
Early recurrence of well-differentiated (G1) neuroendocrine liver metastasis after curative-intent surgery: Risk factors and outcome.J Surg Oncol. 2018 Dec;118(7):1096-1104. doi: 10.1002/jso.25246. Epub 2018 Sep 27. J Surg Oncol. 2018. PMID: 30261105
-
Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery.J Gastrointest Surg. 2017 Dec;21(12):2039-2047. doi: 10.1007/s11605-017-3491-1. Epub 2017 Jul 25. J Gastrointest Surg. 2017. PMID: 28744737
-
Impact of parenchymal preserving surgery on survival and recurrence after liver resection for colorectal liver metastasis.ANZ J Surg. 2018 Jan;88(1-2):66-70. doi: 10.1111/ans.13588. Epub 2016 Apr 25. ANZ J Surg. 2018. PMID: 27111217
-
Liver transplantation for gastroenteropancreatic neuroendocrine liver metastasis: optimal patient selection and perioperative management in the era of multimodal treatments.J Gastroenterol. 2025 Jan;60(1):1-9. doi: 10.1007/s00535-024-02166-z. Epub 2024 Nov 15. J Gastroenterol. 2025. PMID: 39547997 Free PMC article. Review.
-
Total hepatectomy and liver transplantation for metastatic neuroendocrine tumors of the pancreas - a single center experience with ten patients.Langenbecks Arch Surg. 1999 Aug;384(4):370-7. doi: 10.1007/s004230050216. Langenbecks Arch Surg. 1999. PMID: 10473858 Review.
Cited by
-
Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine.Nat Rev Endocrinol. 2020 Oct;16(10):590-607. doi: 10.1038/s41574-020-0391-3. Epub 2020 Aug 24. Nat Rev Endocrinol. 2020. PMID: 32839579 Review.
-
The impact of surgery in metastatic pancreatic neuroendocrine tumors: a competing risk analysis.Endocr Connect. 2019 Mar 1;8(3):239-251. doi: 10.1530/EC-18-0485. Endocr Connect. 2019. PMID: 30726772 Free PMC article.
-
Neuroendocrine liver metastasis from the small intestine: Is surgery beneficial for survival?Orphanet J Rare Dis. 2021 Jan 14;16(1):30. doi: 10.1186/s13023-021-01677-9. Orphanet J Rare Dis. 2021. PMID: 33446229 Free PMC article.
-
Higher Tumor Burden Status Dictates the Impact of Surgical Margin Status on Overall Survival in Patients Undergoing Resection of Intrahepatic Cholangiocarcinoma.Ann Surg Oncol. 2023 Apr;30(4):2023-2032. doi: 10.1245/s10434-022-12803-7. Epub 2022 Nov 17. Ann Surg Oncol. 2023. PMID: 36396868
-
Management of Gastrointestinal Neuroendocrine Tumors.Clin Med Insights Endocrinol Diabetes. 2019 Oct 24;12:1179551419884058. doi: 10.1177/1179551419884058. eCollection 2019. Clin Med Insights Endocrinol Diabetes. 2019. PMID: 31695546 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials